AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
Zimmer Biomet (ZBH) Opens New ZBEdge Centre in Singapore
by Zacks Equity Research
Zimmer Biomet (ZBH) CEC will function as the interface between healthcare professionals and the company through engaging and interactive training across all product portfolios.
Bruker (BRKR) Q4 Earnings Meet Estimates, Revenues Surpass
by Zacks Equity Research
Robust performance by the BSI and BEST segments drove Bruker's (BRKR) fourth-quarter top line.
DexCom (DXCM) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth and solid new customer additions.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
DaVita's (DVA) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q4 top line.
Phibro (PAHC) Q2 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
Phibro (PAHC) reports better-than-expected earnings for the fiscal second quarter. Robust performances by the Animal Health and Mineral Health segments drove the top line.
Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.
Illumina (ILMN) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Record shipments for both clinical and research with strength in oncology testing, genetic disease testing, and population genomics drove Illumina (ILMN) Q4 revenues.
AMN Healthcare Services (AMN) Stock Moves -1.46%: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed at $103.75 in the latest trading session, marking a -1.46% move from the prior day.
AMN Healthcare Services (AMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AMN Healthcare (AMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
LabCorp (LH) reports better-than-expected results for the fourth quarter, with solid contributions from the Drug Development business driving the top line.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its diagnostics business.
STERIS (STE) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
STERIS (STE) reports better-than-expected earnings for the third quarter of fiscal 2022 and robust segmental growth driving the top line.
Baxter (BAX) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Baxter's (BAX) strong product portfolio.
What's in the Cards for Henry Schein (HSIC) in Q4 Earnings?
by Zacks Equity Research
Solid demand in the global dental market along with an increase in COVID-19 test demand are likely to have contributed to Henry Schein's (HSIC) Q4 performance.
AMN Healthcare (AMN) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
AMN Healthcare (AMN) could produce exceptional returns because of its solid growth attributes.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.
Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength across its business segments.
CVS Health (CVS) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Strength in all three operating segments drove CVS Health's (CVS) revenues in the fourth quarter of 2021.
QIAGEN (QGEN) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
High demand for COVID-19 test products and improving trends in the non-COVID portfolio drove QIAGEN's (QGEN) fourth-quarter revenues.
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Increase in number of orders for Cologuard and new study findings supporting the Oncotype DX are likely to have contributed to Exact Sciences' (EXAS) Q4 performance.
Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.
AMN Healthcare (AMN) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
AMN Healthcare (AMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
IDEXX's (IDXX) CAG Diagnostic Sales Gain, Cost Woe Stays
by Zacks Equity Research
IDEXX (IDXX) witnesses continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.